Penn Medicine Provider
Obesity Medicine, Diabetes, Endocrinology
Anastassia Amaro, MD
5.0
(328)
Accepting new patients
Sees patients age 18 and up
Penn Endocrinology Perelman
View 3 additional locations
Schedule onlineCall 215-662-2300

About me

  • Medical Director, Penn Metabolic Medicine
  • Professor of Clinical Medicine (Endocrinology, Diabetes and Metabolism)

Education and training

  • Medical School: Sechenov I Moscow Medical Institute
  • Residency: Sechenov I Moscow Medical Institute
  • Residency: Advocate Lutheran General Hospital
  • Fellowship: Barnes-Jewish Hospital - Washington University, St. Louis

What my patients think about me

Average Rating
5.0

329 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

June 2025
5.0
5.0
very helpful.
May 2025
5.0
5.0
knowledgeable
May 2025
5.0
5.0
explanations that are easy to understand.
May 2025
5.0
5.0
She is well prepared, thorough, articulate, and intelligent. Dr. Amaro listens to my questions and responds in a meaningful manner.

Insurance accepted

My Locations

Learn about location
Learn about location
Learn about location
Learn about location

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Dr. Amaro is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

Marianne Riordan, Elizabeth Sevrukov, Anastassia Amaro Glucagon-Like Peptide-1 Receptor Agonists in Post-Bariatric Hypoglycemia: A Retrospective Chart Review , 32nd European Congress on Obesity: 2025

Caturano A, Amaro A, Berra CC, Conte C. Sarcopenic obesity and weight loss-induced muscle mass loss , Curr Opin Clin Nutr Metab Care: 2025

Emily Gleason, BA Lindsay Levine, BA ∙ Iris T. Lee, MD MSCE ∙ Nathanael Koelper, MPH ∙ Anastassia Amaro, MD ∙ Anuja Dokras, MD, MHCI, PhD Effect of Glucagon-Like Peptide 1 Agonist Medications on Weight Loss in Patients with and Without Polycystic Ovary Syndrome , Fertility and Sterility: 2025

Ariana M Chao 1, Simeon Taylor 2, Molly Moore 3, Anastassia Amaro 4, Thomas A Wadden 3 Evolving Approaches for Pharmacological Therapy of Obesity , Annu Rev Pharmacol Toxicol : 2024

Thomas A Wadden, Ariana M Chao, Molly Moore, Jena S Tronieri, Adam Gilden, Anastassia Amaro, Sharon Leonard, John M Jakicic The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities , Curr Obes Rep: 2023

Authors: Emily Gleason BA, Lindsay Levine BA, Iris T. Lee, MD, Nathanael Koelper, MPH, Anastassia Amaro, MD, Anuja Dokras, MD, MHCI, PhD Effect of Glucagon-Like Peptide 1 Receptor Agonist Pharmacotherapy on Weight Loss in Patients with and Without Polycystic Ovary Syndrome , ASRM 2023 Scientific Congress: 2023

R. Jones Jr, C. Maskart, J. Radway, A. Amaro, S. Cardillo A Multimodal Curriculum to Improve Medical Student Gender-affirming Communication Skills, poster presentation. , ENDO Society : 2023

A. Rivadeneira Rodriguez, M. Walker, R. Gallop, A. Amaro Single Center Retrospective Matched Cohort Study of glp1ra-Induced Weight Loss in Patients With Post-bariatric Weight Regain vs Non-surgical Controls, poster presentation. , ENDO Society : 2023

Amaro A, Sugimoto D, Wharton S. Efficacy and safety of semaglutide for weight management: evidence from the STEP program , Postgrad Med, 134(Sup1): 2023,5-17

Amaro A, Skolnik NS, Sugimoto D. Cardiometabolic risk factors efficacy of semaglutide in the STEP program. , Postgrad Med, 134(sup1): 2023,18-27